Noninvasive methods to assess the risk of kidney transplant rejection

Expert Review of Clinical Immunology

Volumn 5, Issue 5, 2009, Pages 535-546

  Cravedi, Paolo ^a   Mannon, Roslyn B ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Division of Nephrology   (United States)

Author keywords

Biomarker; CD30; Cylex ; ELISPOT; Immune monitoring; Proteomic; Transplantation

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; CHRONIC GRAFT REJECTION; CLINICAL PRACTICE; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; REVIEW; RISK ASSESSMENT; SURGICAL RISK;

EID: 77949787331     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.09.36     Document Type: Review

References (84)

1. Tantravahi J, Womer KL, Kaplan B. Why hasnt eliminating acute rejection improved graft survival? Annu. Rev. Med. 58, 369-385 (2007).
2. Schwarz A, Gwinner W, Hiss M et al. Safety and adequacy of renal transplant protocol biopsies. Am. J. Transplant. 5, 1992-1996 (2005).
3. Mannon RB, Kirk AD. Beyond histology: novel tools to diagnose allograft dysfunction. Clin. J. Am. Soc. Nephrol. 1, 358-366 (2006).
4. Rush D. Protocol transplant biopsies: an underutilized tool in kidney transplantation. Clin. J. Am. Soc. Nephrol. 1, 138-143 (2006).
5. Rush D. Insights into subclinical rejection. Transplant Proc. 36, 71S-73S (2004).
6. Hirsch HH, Brennan DC, Drachenberg CB et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 79, 1277-1286 (2005).
7. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69(3), 89-95 (2001).
8. Najafian N, Albin MJ, Newell KA. How can we measure immunologic tolerance in humans? J. Am. Soc. Nephrol. 17, 2652-2663 (2006).
9. Hernandez-Fuentes MP, Warrens AN, Lechler RI. Immunologic monitoring. Immunol. Rev. 196, 247-264 (2003).
10. Pearl JP, Parris J, Hale DA et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am. J. Transplant. 5, 465-474 (2005).
11. Noris M, Casiraghi F, Todeschini M et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J. Am. Soc. Nephrol. 18, 1007-1018 (2007).
12. Ruggenenti P, Perico N, Gotti E et al. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 84, 956-964 (2007).
13. Salama AD, Remuzzi G, Harmon WE et al. Challenges to achieving clinical transplantation tolerance. J. Clin. Invest. 108, 943-948 (2001).
14. Thomas FT, Lee HM, Lower RR et al. Immunological monitoring as a guide to the management of transplant recipients. Surg. Clin. North Am. 59, 253-281 (1979).
15. Ghobrial II, Morris AG, Booth LJ. Clinical significance of in vitro donor-specific hyporesponsiveness in renal allograft recipients as demonstrated by the MLR. Transpl. Int. 7, 420-427 (1994).
16. Ferraris JR, Tambutti M, Prigoshin N. Improved long-term graft function in kidney transplant recipients with donor antigen-specific hyporeactivity. Pediatr. Transplant. 11, 139-144 (2007).
17. Lefkovits I. Induction of antibody-forming cell clones in microcultures. Eur. J. Immunol. 2, 360-366 (1972).
18. Cattell EL, Cunningham AC, Bal W et al. Limiting dilution analysis: quantification of IL-2 producing allospecific lymphocytes after renal and cardiac transplantation. Transpl. Immunol. 2, 300-307 (1994).
19. Vaessen LM, Daane CR, Maat AP et al. T helper frequencies in peripheral blood reflect donor-directed reactivity in the graft after clinical heart transplantation. Clin. Exp. Immunol. 118, 473-479 (1999).
20. Mashishi T, Gray CM. The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes. Clin. Chem. Lab. Med. 40, 903-910 (2002).
21. Hricik DE, Rodriguez V, Riley J et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon- independently predicts renal function in kidney transplant recipients. Am. J. Transplant. 3, 878-884 (2003).
22. Najafian N, Salama AD, Fedoseyeva EV et al. Enzyme-linked immunosorbent spot assay analysis of peripheral blood lymphocyte reactivity to donor HLA-DR peptides: potential novel assay for prediction of outcomes for renal transplant recipients. J. Am. Soc. Nephrol. 13, 252-259 (2002).
23. Poggio ED, Augustine JJ, Clemente M et al. Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection. Transplantation 83, 847-852 (2007).
24. Augustine JJ, Poggio ED, Heeger PS et al. Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-enzyme-linked immunosorbent spots. Transplantation 86, 529-534 (2008).
25. Bestard O, Nickel P, Cruzado JM et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J. Am. Soc. Nephrol. 19, 1419-1429 (2008).
26. VanBuskirk AM, Burlingham WJ, Jankowska-Gan E et al. Human allograft acceptance is associated with immune regulation. J. Clin. Invest. 106, 145-155 (2000).
27. van Besouw NM, van der Mast BJ, van de Wetering J et al. Tapering immunosuppressive therapy significantly improves in vivo cutaneous delayed type hypersensitivity responses. Transpl. Immunol. 19, 229-234 (2008).
28. Wramner L, Olausson M, Soderstrom T et al. Evidence of donor-specific cellular suppressor activity in donor-specific cell-mediated lympholysis unresponsiveness in renal transplant patients. Transplantation 44, 390-395 (1987).
29. Burlingham WJ, Grailer A, Sollinger HW. Changes in donor-specific cell-mediated lympholysis (CML) response associated with success of early steroid withdrawal in DST-azathioprine-treated renal transplant recipients. Transplant Proc. 21, 1818-1819 (1989).
30. Weimar W, Rischen-Vos J, de Kuiper P et al. Tapering immunosuppression in recipients of living donor kidney transplants. Nephrol. Dial. Transplant. 19(Suppl. 4), iv61-iv63 (2004).
31. Kowalski RJ, Post DR, Mannon RB et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 82, 663-668 (2006).
32. Rodrigo E, Arias M. A practical approach to immune monitoring in kidney transplantation. Minerva Urol. Nefrol. 59, 337-352 (2007).
33. Israeli M, Yussim A, Mor E et al. Preceeding the rejection: in search for a comprehensive post-transplant immune monitoring platform. Transpl. Immunol. 18, 7-12 (2007).
34. Zeevi A, Britz JA, Bentlejewski CA et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transpl. Immunol. 15, 17-24 (2005).
35. Orosz CG, Zinn NE, Sirinek LP et al. In vivo mechanisms of alloreactivity. II. Allospecificity of cytotoxic T lymphocytes in sponge matrix allografts as determined by limiting dilution analysis. Transplantation 41, 84-92 (1986).
36. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3, 199-210 (2003).
37. Meloni F, Vitulo P, Bianco AM et al. Regulatory CD4+CD25+ T cells in the peripheral blood of lung transplant recipients: correlation with transplant outcome. Transplantation 77, 762-766 (2004).
38. Muthukumar T, Dadhania D, Ding R et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N. Engl. J. Med. 353, 2342-2351 (2005).
39. Korczak-Kowalska G, Wierzbicki P, Bocian K et al. The influence of immuosuppressive therapy on the development of CD4+CD25+ T cells after renal transplantation. Transplant Proc. 39, 2721-2723 (2007).
40. San Segundo D, Fabrega E, Lopez-Hoyos M et al. Reduced numbers of blood natural regulatory T cells in stable liver transplant recipients with high levels of calcineurin inhibitors. Transplant Proc. 39, 2290-2292 (2007).
41. Cortesini R, Renna-Molajoni E, Cinti P et al. Tailoring of immunosuppression in renal and liver allograft recipients displaying donor specific T-suppressor cells. Hum. Immunol. 63, 1010-1018 (2002).
42. Suciu-Foca N, Manavalan JS, Cortesini R. Generation and function of antigen-specific suppressor and regulatory T cells. Transpl. Immunol. 11, 235-244 (2003).
43. Manavalan JS, Kim-Schulze S, Scotto L et al. Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int. Immunol. 16, 1055-1068 (2004).
44. Cravedi P, Mannon RB, Remuzzi G. Lymphocyte depletion for kidney transplantation: back to the past? Nat. Clin. Pract. Nephrol. 4, 534-535 (2008).
45. Hickman SP, Turka LA. Homeostatic T cell proliferation as a barrier to T cell tolerance. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 360, 1713-1721 (2005).
46. Alvarez CM OG, Giraldo MC, Pelzl S et al. Evaluation of T-cell receptor repertoires in patients with long-term renal allograft survival. Am. J. Transplant. 5, 746-756 (2005).
47. Heslan JM BG, Le Luduec JB, Guillonneau C et al. Accumulation of T cells with potent regulatory properties and restricted V-7-TCR rearrangements in tolerated allografts. Transplantation 27, 1476-1484 (2005).
48. Baeten D LS, Braud C, Braudeau C et al. Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J. Am. Soc. Nephrol. 17, 294-304 (2006).
49. Vasconcellos LM, Schachter AD, Zheng XX et al. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 66, 562-566 (1998).
50. Sawitzki B, Bushell A, Steger U et al. Identification of gene markers for the prediction of allograft rejection or permanent acceptance. Am. J. Transplant. 7, 1091-1102 (2007).
51. Deng MC, Eisen HJ, Mehra MR et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am. J. Transplant. 6, 150-160 (2006).
52. Brouard S, Mansfield E, Braud C et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc. Natl Acad. Sci. USA 104, 15448-15453 (2007).
53. Martinez-Llordella M, Lozano JJ, Puig-Pey I et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J. Clin. Invest. 118, 2845-2857 (2008).
54. Cruzado JM, Bestard O, Grinyo JM. Control of anti-donor antibody production post-transplantation: conventional and novel immunosuppressive therapies. Contrib. Nephrol. 162, 117-128 (2009).
55. Akalin E, Pascual M. Sensitization after kidney transplantation. Clin. J. Am. Soc. Nephrol. 1, 433-440 (2006).
56. Kaczmarek I, Deutsch MA, Kauke T et al. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp. Clin. Transplant. 6, 229-235 (2008).
57. Girnita AL, McCurry KR, Zeevi A. Increased lung allograft failure in patients with HLA-specific antibody. Clin. Transpl. 231-239 (2007).
58. Susal C, Dohler B, Sadeghi M et al. HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a collaborative transplant study report. Transplantation 87, 1367-1371 (2009).
59. Faulk WP, Rose M, Meroni PL et al. Antibodies to endothelial cells identify myocardial damage and predict development of coronary artery disease in patients with transplanted hearts. Hum. Immunol. 60, 826-832 (1999).
60. Gloor J, Cosio F, Lager DJ et al. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am. J. Transplant. 8, 1367-1373 (2008).
61. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med. 359, 242-251 (2008).
62. Trivedi HL, Terasaki PI, Feroz A et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 87, 1555-1561 (2009).
63. Kovac J, Arnol M, Vidan-Jeras B et al. Does pretransplant soluble CD30 serum concentration affect deceased-donor kidney graft function 3 years after transplantation? Transplant Proc. 40, 1357-1361 (2008).
64. Heinemann FM, Rebmann V, Witzke O et al. Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation. Transplantation 83, 706-711 (2007).
65. Vaidya S, Partlow D, Barnes T et al. Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies. Transplantation 82, 1606-1609 (2006).
66. Hancock WW, Wang L, Ye Q et al. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr. Opin. Immunol. 15, 479-486 (2003).
67. Grebe SO, Mueller TF. Immune monitoring in organ transplantation using neopterin. Curr. Drug Metab. 3, 189-202 (2002).
68. Li B, Hartono C, Ding R et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N. Engl. J. Med. 344, 947-954 (2001).
69. Muthukumar T, Ding R, Dadhania D et al. Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/ perforin lytic pathway, is hyperexpressed during acute rejection of renal allografts. Transplantation 75, 1565-1570 (2003).
70. Hauser IA, Spiegler S, Kiss E et al. Prediction of acute renal allograft rejection by urinary monokine induced by IFN-? (MIG). J. Am. Soc. Nephrol. 16, 1849-1858 (2005).
71. Tatapudi RR, Muthukumar T, Dadhania D et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int. 65, 2390-2397 (2004).
72. Schaub S, Rush D, Wilkins J et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J. Am. Soc. Nephrol. 15, 219-227 (2004).
73. Quintana LF, Sole-Gonzalez A, Kalko SG et al. Urine proteomics to detect biomarkers for chronic allograft dysfunction. J. Am. Soc. Nephrol. 20, 428-435 (2009).
74. Grimm PC, McKenna R, Nickerson P et al. Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. J. Am. Soc. Nephrol. 10, 1582-1589 (1999).
75. Zarkhin V, Sarwal MM. Microarrays: monitoring for transplant tolerance and mechanistic insights. Clin. Lab. Med. 28(3), 385-410 (2008).
76. Shah S, Sarwal MM. Microarrays: interrogating the transplant transcriptosome. Clin. Transpl. 18(3), 261-267 (2004).
77. Wright PK, Raine C. Molecular heterogeneity in acute renal allograft rejection and DNA microarrays. N. Engl. J. Med. 349, 2269 (2003).
78. Mannon RB, Hoffmann SC, Kampen RL et al. Molecular evaluation of BK polyomavirus nephropathy. Am. J. Transplant. 5, 2883-2893 (2005).
79. Hoffmann SC, Kampen RL, Amur S et al. Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation 74, 916-923 (2002).
80. Hoffmann SC, Hale DA, Kleiner DE et al. Functionally significant renal allograft rejection is defined by transcriptional criteria. Am. J. Transplant. 5, 573-581 (2005).
81. Varagunam M, Yaqoob MM, Dohler B et al. C3 polymorphisms and allograft outcome in renal transplantation. N. Engl. J. Med. 360, 874-880 (2009).
82. Alakulppi NS, Kyllonen LE, Jantti VT et al. Cytokine gene polymorphisms and risks of acute rejection and delayed graft function after kidney transplantation. Transplantation 78, 1422-1428 (2004).
83. Brouarda S, Mansfield E, Braud C et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc. Natl Acad. Sci. USA 104, 15448-15453 (2007).
84. Ballet C, Roussey-Kesler G, Aubin JT et al. Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft. Am. J. Transplant. 6, 2796-2801 (2006).